Azmal Sarker1, Hyung-Jun Im, Gi Jeong Cheon, Hyun Hoon Chung, Keon Wook Kang, June-Key Chung, E Edmund Kim, Dong Soo Lee. 1. From the *Department of Nuclear Medicine, Seoul National University Hospital; †Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy; ‡Cancer Research Institute, Seoul National University Hospital; and §Department of Obstetrics and Gynecology, College of Medicine, Seoul National University, Seoul, Korea; and ∥Department of Radiological Science, University of California at Irvine, CA.
Abstract
PURPOSE: We conducted a meta-analysis to evaluate the prognostic value of the SUVmax measured in pretreatment primary lesions and metastatic lymph nodes (LNs) on 18F-FDG PET scans in patients with uterine cervical cancer. METHODS: A systematic search of EMBASE and MEDLINE was performed using the keywords "positron emission tomography (PET)," "uterine cervical cancer," and "prognosis." Event-free survival and overall survival were evaluated as outcomes. The impact of SUVmax on survival was measured by the effect size of the hazard ratio (HR). RESULTS: Fourteen eligible studies including 1150 patients were analyzed. Patients with a high primary SUVmax showed a worse prognosis, with an HR of 2.66 (95% confidence interval [CI], 1.90-3.74; P < 0.00001) for adverse events and an HR of 2.45 (95% CI, 1.74-3.45; P < 0.00001) for death. Patients with high SUVmax in metastatic pelvic LN (PLN) showed a worse prognosis, with an HR of 2.92 (95% CI, 1.94-4.39; P < 0.00001) for adverse events and an HR of 2.66 (95% CI, 1.60-4.43; P = 0.0002) for SUVmax in PLN for death. In addition, high SUVmax in metastatic para-aortic LN was associated with a worse prognosis, with an HR of 4.41 (95% CI, 2.32-8.38; P < 0.00001) for death. CONCLUSIONS: Patients with uterine cervical cancer and a high SUVmax primary lesion, PLN, or para-aortic LN are at higher risk of adverse events or death.
PURPOSE: We conducted a meta-analysis to evaluate the prognostic value of the SUVmax measured in pretreatment primary lesions and metastatic lymph nodes (LNs) on 18F-FDG PET scans in patients with uterine cervical cancer. METHODS: A systematic search of EMBASE and MEDLINE was performed using the keywords "positron emission tomography (PET)," "uterine cervical cancer," and "prognosis." Event-free survival and overall survival were evaluated as outcomes. The impact of SUVmax on survival was measured by the effect size of the hazard ratio (HR). RESULTS: Fourteen eligible studies including 1150 patients were analyzed. Patients with a high primary SUVmax showed a worse prognosis, with an HR of 2.66 (95% confidence interval [CI], 1.90-3.74; P < 0.00001) for adverse events and an HR of 2.45 (95% CI, 1.74-3.45; P < 0.00001) for death. Patients with high SUVmax in metastatic pelvic LN (PLN) showed a worse prognosis, with an HR of 2.92 (95% CI, 1.94-4.39; P < 0.00001) for adverse events and an HR of 2.66 (95% CI, 1.60-4.43; P = 0.0002) for SUVmax in PLN for death. In addition, high SUVmax in metastatic para-aortic LN was associated with a worse prognosis, with an HR of 4.41 (95% CI, 2.32-8.38; P < 0.00001) for death. CONCLUSIONS:Patients with uterine cervical cancer and a high SUVmax primary lesion, PLN, or para-aortic LN are at higher risk of adverse events or death.
Authors: Hyung-Jun Im; Meiyappan Solaiyappan; Inki Lee; Tyler Bradshaw; Najat C Daw; Fariba Navid; Barry L Shulkin; Steve Y Cho Journal: Am J Nucl Med Mol Imaging Date: 2018-12-20
Authors: A Martinez; M Voglimacci; A Lusque; A Ducassou; L Gladieff; N Dupuis; M A Angeles; C Martinez; Y Tanguy Le Gac; E Chantalat; A Hitzel; F Courbon; G Ferron; E Gabiache Journal: Eur J Nucl Med Mol Imaging Date: 2020-01-08 Impact factor: 9.236
Authors: Jonathan S Berek; Koji Matsuo; Brendan H Grubbs; David K Gaffney; Susanna I Lee; Aoife Kilcoyne; Gi Jeong Cheon; Chong Woo Yoo; Lu Li; Yifeng Shao; Tianhui Chen; Miseon Kim; Mikio Mikami Journal: J Gynecol Oncol Date: 2018-12-28 Impact factor: 4.401